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Abstract
Background: Primary jejunal gastrinomas are exceedingly rare, and data for long-term follow-up is limited. Until
now, only six cases of gastrinomas arising from the jejunum have been reported in the English literature.
Case Presentation: Presented is a case of a primary gastrinoma located in the proximal jejunum. After surgical
resection of the tumor, eugastrinemia was quickly achieved and after a 10-year follow-up period, the patient was
still disease-free.
Conclusions: This case report demonstrates that surgical resection of a primary jejunal gastrinoma without
evidence of metastasis can be curative, with a good long-term prognosis.
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Background
A gastrinoma is a non-beta islet cell tumor which se-
cretes gastrin. The hypergastrinemic state caused by a
gastrinoma results in multiple recurrent and often re-
fractory ulcers in the gastrointestinal tract and is known
as Zollinger-Ellison syndrome (ZES). In 1955, ZES was
originally reported with the presenting triad of recurrent
peptic ulceration, hypersecretion of gastric acid, and the
presence of a non-beta islet cell tumor of the pancreas
[1]. Since then, it has been well-documented that most
primary gastrinomas are found mainly in the duodenum,
pancreatic head, or lymph nodes within the traditional
gastrinoma triangle which is demarcated by the junction
of the cystic duct and common bile duct, junction of the
second and third portion of the duodenum, and the
junction between the neck and body of the pancreas [2].
However, there have been reported cases of gastrino-
mas outside of these areas, which have been called
ectopic gastrinomas. About 5.6 % of patients have a pri-
mary gastrinoma located in an ectopic site [3]. Primary
jejunal gastrinomas are exceedingly rare, and data for
long-term follow-up is limited. Until now, only six cases
of gastrinomas arising from the jejunum have been
reported in the English literature [3–7]. Presented is a case
of a primary gastrinoma located in the proximal jejunum,
which is a possible diagnosis when a jejunum tumor is
detected by radiographic examination. Ten years after
segmental resection of the jejunum containing the gastri-
noma, the patient was still eugastrinemic and asymptom-
atic, and there was no evidence of tumor recurrence.
Case presentation
In September 2003, a 34-year-old male patient presented
at the Department of Surgery at Shin Kong Wu Ho-Su
Memorial Hospital (Taipei, Taiwan) with abdominal full-
ness and discomfort that had gradually developed over
the past year. Upon further review, the patient had an
8-year history of heartburn which was only slightly
relieved by antacids. Bowel habits were normal with-
out mention of tarry or bloody stool. Also, he did not
notice recent body weight loss.
Abdominal ultrasound in September of 2003
showed an abdominal mass in the left upper quadrant
of his abdomen. An abdominal computed tomography
(CT) confirmed a left upper quadrant abdominal mass
(approximately 7 cm × 6 cm × 4 cm) near the proximal
jejunum (Fig. 1). Esophagogastroduodenoscopy and
small-bowel endoscopy revealed several esophageal,
gastric, duodenal, and upper jejunal ulcers (Fig. 2).
Serum gastrin levels were elevated (451.00 pg/mL;
normal range 30–100 pg/mL). Serum tumor markers
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including alpha-fetoprotein (AFP), carcinoembryonic anti-
gen (CEA), and carbohydrate antigen 19-9 (CA 19-9) were
within normal limits. The presence of multiple ulcers, ul-
cers distal to the first portion of the duodenum, refractory
symptoms of gastroesophageal reflux disease, and elevated
fasting serum gastrin levels raised the suspicion of
Zollinger-Ellison syndrome. Endoscopic ultrasound (EUS)
was performed to localize a possible tumor in the gastri-
noma triangle but was unable to identify any tumor.
An exploratory laparotomy was performed. At surgery, a
large tumor was identified in the wall of the proximal je-
junum, approximately 3 cm distal to the ligament of Treitz.
Thorough exploration of the abdomen, including the liver,
small intestine, pancreas, stomach, duodenum, mesentery,
and retroperioneal regions in the upper abdomen and con-
comitant intraoperative ultrasonography (US) did not re-
veal any other tumors. Segmental resection of the upper
jejunum, including a 7 cm × 6 cm×4 cm tumor just distal
to the ligament of Treitz, was done, and subsequent
jejunal-jejunal end-to-end anastomosis was performed.
Pathological findings of the jejunal tumor showed a
neuroendocrine tumor consistent with gastrinoma.
Microscopically, the tumor was composed of relatively
uniform cells having centrally located nuclei and eosino-
philic cytoplasm (Fig. 3). The tumor cells were arranged
Fig. 1 Contrast abdominal computed tomography showing a
7 cm × 6 cm × 4 cm mass in the proximal jejunum (white arrow)
Fig. 2 Findings of esophagogastroduodenoscopy and small-bowel endoscopy. a Circumferential reflux esophagitis with superficial ulceration was
observed in the distal esophagus near the gastroesophageal junction. b Gastric ulcers with hemorrhage were noted. c Multiple erosions were
found in the duodenum. d Several upper jejunal ulcers were also noted
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in trabecular and gyriform fashions (Fig. 4). The mitotic
index was low, and no tumor necrosis was found. On
immunohistochemical studies, the tumor cells were
positive for gastrin (Fig. 5).
On the fifth postoperative day, his fasting serum gas-
trin had decreased to 65.8 pg/mL. He was discharged
9 days postoperatively in fair condition without any
complications. The patient was regularly followed up,
and over 10 years after surgery, the patient remains free
of acid regurgitation and abdominal discomfort and is in
good health. Current gastrin levels are normal (75.60 pg/
mL), esophagogastroduodenoscopy revealed no ulcers,
and recent CT and magnetic resonance imaging (MRI)
showed no signs of recurrent tumors.
Discussion
Primary jejunal gastrinomas are exceedingly rare, and
data for long-term follow-up is limited. To our know-
ledge, only six cases of gastrinomas originating from the
jejunal wall have been reported in the English literature
to date (Table 1) [3–7].
Gastrinomas of the jejunum are usually small in size,
with a reported diameter of 0.5–3 cm [4, 5]. There has
only been one case where the tumor was identified pre-
operatively by combined imaging studies [5]. Preopera-
tive imaging studies have failed to identify a primary
tumor in the other reported cases. The unique feature of
our case is that the tumor was large in size, and may be
the largest tumor reported to date. Preoperative ultra-
sound and abdominal CT correctly localized the ectopic
gastrinoma.
Although gastrinomas tend to be slow growing, 60 to
90 % of them were associated with metastases [8–10].
Like other neuroendocrine tumors, malignancy cannot
be established cytologically, but is determined by the
presence of metastases as well as vascular or lymphatic
invasion [11]. Larger gastrinomas are more likely to
metastasize; liver and regional lymph nodes are the most
common sites of metastases. Our case is unusual in that
the tumor was large in size, yet there is no evidence of
distant metastasis.
Many of the gastrinomas are small in size, which
makes preoperative localization highly challenging. Fur-
thermore, since the jejunum is not located within the
gastrinoma triangle, this unexpected localization makes
the diagnosis difficult. A number of tests are used to
localize gastrinomas. CT scan, MRI, and ultrasound are
used widely as the initial methods for localizing gastri-
noma and are excellent for visualization of larger tu-
mors. Somatostatin receptor scintigraphy (SRS) has a
high sensitivity for assessing the extent of the disease. In
Fig. 3 Hematoxylin and eosin stain (×400). The tumor had relatively
uniform cells having centrally located nuclei and
eosinophilic cytoplasm
Fig. 4 Hematoxylin and eosin stain (×100). The tumor cells were
arranged in trabecular and gyriform fashions
Fig. 5 Gastrin stain (×400). Immunohistochemical stains were
positive for gastrin
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recent years, SRS has become the imaging study of
choice for identifying primary tumors and metastatic
lesions in ZES [12–15]. However, the sensitivity of SRS
to detect gastrinomas is highly dependent on its size,
ranging from 30 % for gastrinomas smaller than 1.1 cm
to 96 % for gastrinomas larger than 2 cm [15]. EUS has
a high sensitivity for detection of pancreatic gastrinomas,
ranging from 75 to 100 % [16, 17]. However, EUS is not
as accurate in detecting duodenal gastrinomas [18].
These imaging studies should be used in conjunction to
achieve optimal preoperative assessment of the gastri-
noma. It is important to note that smaller tumors (less
than 1 cm) may often be missed and may require the
use of IOUS to facilitate localization of small lesions that
were not readily visible on preoperative studies. Current
transducers can detect lesions as small as 2 mm [19]. In
our case, preoperative abdominal CT and EUS and intra-
operative US were use for localization of the gastrinoma
and rule out metastatic disease. SRS was not performed
because it was not available at our institute at the time
of diagnosis in 2003.
The discovery of a gastrinoma in the jejunum raises
the question of whether the tumor is a primary or meta-
static lesion. Exhaustive preoperative imaging as well as
careful surgical exploration during laparotomy including
intraoperative ultrasound revealed no additional lesions.
Thus, the large jejunal tumor was considered to be the
primary lesion. Still, it was possible that an occult pri-
mary lesion was missed by EUS, surgical exploration,
and intraoperative ultrasound. However, plasma gastrin
level normalized shortly after the excision of the tumor.
Over 10 years after surgery, the patient is still eugas-
trinemic, and there is no evidence of tumor recurrence
in long-term follow-up. Based on these findings, it is ap-
parent that the jejunal tumor is a solitary primary
gastrinoma.
The current treatment of sporadic, resectable, non-
metastatic gastrinomas is early surgical exploration and
surgical resection. Reviews have stated that for sporadic
gastrinomas, the initial postoperative cure rate is
approximately 50–60 %, and the long-term cure rate is
35–40 % [20–22]. There are a limited number of studies
addressing the long-term follow-up of ectopic gastrino-
mas. Wu el al. treated eight patients with ectopic gastri-
nomas from 1982 to 1997, seven patients were cured
biochemically after resection, and five patients were
cured with a mean follow-up of 7.5 years (range, 0.4–
11.7 years) [3]. In our case, after surgical excision of the
gastrinoma located in the jejunum as the lone method of
treatment, the patient was still eugastrinemic and
asymptomatic without tumor recurrence at 10-year
follow-up. Among the six reported cases of gastrinomas
originating from the jejunal wall, only three cases re-
ported a follow-up period of more than 3 years [3, 5, 6].
Antonioli et al. reported a case with gastrinomas in the
jejunal wall with metastatic lymph nodes in the adjacent
mesentery. After resection of the involved jejunum and
mesentery, she remained eugastrinemic 3 years after op-
eration [5]. Katoh et al. reported a case of gastrinoma in
the jejunum and jejunal mesentery with multiple liver










M/66 5650 Around the ligament of Treitz 3 Tumor excision 6 months No recurrence




F/46 730–980 5 nodules in the jejunal wall,
10 cm distal to the ligament
of Treitz, with adjacent
mesenteric lymph node
metastasis
0.4–3 Partial resection of
involved jejunum
and mesentery





M/25 764 A primary gastrinoma in the jejunal
wall just distal to the ligament of
Treitz. Two more tumors in adjacent
jejunal mesentery. Multiple liver
metastases
NP Excision of jejunum
tumors + remnant
gastrectomy




M/63 787–1913 A primary gastrinoma in the
submucosa of the jejunum. A lymph
node metastasis (1.5 cm) in the
jejunal mesentery 5 cm distal to
the ligament of Treitz
NP Partial resection of jejunum
and pancreatocduodenectomy
(on the suspicion of multiple
primary sites)




M/35 460 Jejunum (distance from the ligament
of Treitz not mentioned)
NP Tumor resection by
enucleation
134 months Elevated FSG at
2 years, local
recurrence at 11 years
M male, F female, FSG fasting serum gastrin, NP not provided
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metastases. Ten years after tumor resection, the patient
is alive and there was stabilization of liver metastasis [6].
Wu et al. reported a case of primary jejunal gastrinoma
treated by enucleation, who had biochemical recurrence
at 2 years after surgery and local recurrence detected by
SRS at 11 years after surgery [3].
Conclusions
Although primary jejunal gastrinomas are rare occur-
rences, it should be considered during the differential
diagnosis of jejunal tumors if classic symptoms, such as
uncontrolled reflux, non-healing mucosal ulcers or diar-
rhea are present. Here, we report an extremely rare case
of a primary jejunal gastrinoma in which the tumor may
be the largest reported to date. Over 10 years after seg-
mental resection of the jejunum containing the gastri-
noma, the patient is still eugastrinemic and asymptomatic
with no evidence of tumor recurrence.
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